320 507

Cited 5 times in

Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.

DC Field Value Language
dc.contributor.authorJoo, NS-
dc.contributor.authorKim, SM-
dc.contributor.authorKim, KM-
dc.contributor.authorKim, CW-
dc.contributor.authorKim, B-
dc.contributor.authorLee, DJ-
dc.date.accessioned2012-04-27-
dc.date.available2012-04-27-
dc.date.issued2011-
dc.identifier.issn0513-5796-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/6608-
dc.description.abstractPURPOSE: Low grade inflammation is a well-known characteristic in obese subjects. We investigated body weight changes and inflammatory markers after 12-week intervention trial.



MATERIALS AND METHODS: Twenty-six obese subjects were enrolled and 19 (13 men and 6 women) completed the study. Sibutramine is an FDA-approved drug for body weight control; therefore, we chose this drug as the standard treatment medication in this study. Patients were randomly allocated to receive an anti-inflammatory agent (Diacerein treatment group; n = 12) or placebo (n = 7) for 12 weeks. Anthropometry, body proportion by dual-energy X-ray absorptiometry, and metabolic parameters at the beginning and end of study were measured and compared.



RESULTS: The treatment group had a tendency towards more reduction in anthropometry as compared to the placebo group, in body weight reduction (-7.0 kg vs. -4.6 kg), body mass index (-2.51 kg/m² vs. -1.59 kg/m²), and waist circumference (-7.3 cm vs. -4.4 cm). These reductions were not statistically significant. Changes in levels of high-sensitivity C-reactive protein and adiponectin in the treatment group were more favorable than in the placebo group.



CONCLUSION: This small pilot study showed no statistical difference for changes in anthropometry, and inflammatory markers between the two groups. Therefore, we could not find any additional effects of Diacerein on weight loss and inflammatory variables in this study.
-
dc.language.isoen-
dc.subject.MESHAbsorptiometry, Photon-
dc.subject.MESHAdiponectin/blood-
dc.subject.MESHAdult-
dc.subject.MESHAnthraquinones/*therapeutic use-
dc.subject.MESHAnti-Inflammatory Agents/*therapeutic use-
dc.subject.MESHAppetite Depressants/therapeutic use-
dc.subject.MESHC-Reactive Protein/analysis-
dc.subject.MESHCyclobutanes/*therapeutic use-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInflammation-
dc.subject.MESHLipoproteins, LDL/blood-
dc.subject.MESHMale-
dc.subject.MESHObesity/*drug therapy/immunology-
dc.subject.MESHPilot Projects-
dc.subject.MESHTumor Necrosis Factor-alpha/blood-
dc.subject.MESHWaist Circumference/drug effects/immunology-
dc.subject.MESHWeight Loss/drug effects/*immunology-
dc.titleChanges of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study.-
dc.typeArticle-
dc.identifier.pmid21319341-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051215/-
dc.contributor.affiliatedAuthor주, 남석-
dc.contributor.affiliatedAuthor김, 광민-
dc.contributor.affiliatedAuthor김, 범택-
dc.contributor.affiliatedAuthor이, 득주-
dc.type.localJournal Papers-
dc.identifier.doi10.3349/ymj.2011.52.2.242-
dc.citation.titleYonsei medical journal-
dc.citation.volume52-
dc.citation.number2-
dc.citation.date2011-
dc.citation.startPage242-
dc.citation.endPage248-
dc.identifier.bibliographicCitationYonsei medical journal, 52(2):242-248, 2011-
dc.identifier.eissn1976-2437-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Family Practice & Community Health
Files in This Item:
21319341.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse